RADIOPHARMACEUTICAL THERAPY OF LIVER AND BRAIN METASTASES

Course overview

UAN: 0018-0000-18-203-H01-P UAN: 0018-0000-18-203-H01-T RELEASE: 10/22/2018 EXPIRE: 10/22/2021 CREDITS: 1.0 LEARNING OBJECTIVES: 1. Describe Selective Internal Radiation Therapy (SIRT) treatment of hepatic metastatic disease. 2. Describe the use of yttrium-90 microspheres for treating hepatic metastatic disease including patient selection, dosing, side effects and patient response. 3. Describe the use of the Gliasite Radiotherapy System for treating residual disease in glioblastoma patients including the radioactive agents and their clinical application. 4. Understand the basics behind the use of I-125 or Cs-131 to treat brain cancer after surgical debulking. NOTE: An annual subscription for Purdue¿s nuclear pharmacy recertification program provides access to both the continuing education component of the program and the ¿Radiopharmacy Portal,¿ a reference resource for practitioners. Subscriptions to the continuing educational offerings, which have been accredited through ACPE and BPS, can be purchased for an annual fee of $195 for nuclear pharmacists and $95 for nuclear pharmacy technicians.